© Drug Hunter Inc. 2018-2023
Home > “compound 60b”
RSV D486N-mut. fusion protein inh.
oral antiviral clinical candidate
from lower barrier to atropisomerism of lead
Bioorg. Med. Chem., Oct. 31, 2020
Taisho Pharmaceutical, Saitama, JP
“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year